Compare RLMD & CHMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLMD | CHMG |
|---|---|---|
| Founded | 2004 | 1833 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.7M | 257.8M |
| IPO Year | 2012 | 1995 |
| Metric | RLMD | CHMG |
|---|---|---|
| Price | $7.10 | $53.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | $12.40 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 1.8M | 3.5K |
| Earning Date | 05-11-2026 | 04-17-2026 |
| Dividend Yield | N/A | ★ 2.53% |
| EPS Growth | ★ 45.28 | N/A |
| EPS | N/A | ★ 3.14 |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | $37.32 |
| Revenue Next Year | N/A | $9.13 |
| P/E Ratio | ★ N/A | $17.14 |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $0.24 | $40.71 |
| 52 Week High | $7.41 | $65.50 |
| Indicator | RLMD | CHMG |
|---|---|---|
| Relative Strength Index (RSI) | 66.73 | 51.29 |
| Support Level | $3.49 | $52.75 |
| Resistance Level | $7.41 | $57.00 |
| Average True Range (ATR) | 0.46 | 1.58 |
| MACD | 0.02 | 0.41 |
| Stochastic Oscillator | 84.62 | 71.45 |
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.